🇺🇸 FDA
Patent

US 10471061

Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders

granted A61KA61K31/506A61K31/517

Quick answer

US patent 10471061 (Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Nov 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/506, A61K31/517, A61K31/527, A61P